APP and Alzheimer disease: Recent studies have also shown that prebiotic mannan oligosaccharide (MOS) treatment significantly decreased the accumulation of Aβ and inhibited the expression of APP and BACE1 in the brains of AD mice (Wang et al., 2019; Liu et al., 2021).